Citadel Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Citadel Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-15,400	Closed	-$575K	–	15183
2021 Q2	$575K	Sell	15,400 -33,500	-69%	-$1.03M	﹤0.01%	9743
2021 Q1	$1.25M	Buy	48,900 +32,100	+191%	+$820K	﹤0.01%	7552
2020 Q4	$370K	Buy	+16,800	New	+$370K	﹤0.01%	8707
2020 Q3	–	Sell	-17,800	Closed	-$452K	–	11032
2020 Q2	$452K	Buy	+17,800	New	+$383K	﹤0.01%	7270
2019 Q1	–	Sell	-12,400	Closed	-$133K	–	10118
2018 Q4	$133K	Buy	+12,400	New	+$163K	﹤0.01%	8122

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Citadel Advisors's DRNA Position: Q4 2021 in Review

Citadel Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 261,200 shares — an estimated $5.27M sold.

Citadel Advisors first reported a position in DRNA in Q1 2015 and held it in 16 quarters. The position peaked at $44.9M in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Citadel Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Citadel Advisors sold 261,200 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5.27M.
Citadel Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 16 quarters.
Citadel Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $44.9M in Q4 2019.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.